ERBB2 and breast carcinoma: Accordingly, in vivo and in silico analyses of human breast cancer confirmed that the amplification of ERBB2 in combination with the overexpression of p130Cas induces a higher proliferation rate and an increased number of distant metastases, as well as a correlation with poor prognosis (Cabodi et al., 2006; Tornillo et al., 2011).